Monograph
B01AA04 - Phenprocoumon |
Propably not porphyrinogenic |
PNP |
Rationale
Phenprocoumon is metabolized by CYP 2C9, 3A4 and 2C8, but induction or inhibition of the CYP enzymes are not observed or suspected.
Chemical description
Phenprocoumon is a coumarin derivate.
Therapeutic characteristics
Phenprocoumon is a vitamin K antagonist that acts as a long acting oral anticoagulant.
It is administered orally and has a half- life of 5-9 days (Ufer 2004).
Metabolism and pharmacokinetics
In vitro, CYP2C9 and CYP3A4 is found to be the main catalyzing enzymes of the R-enantiomer of phenprocoumon hydroxylation while CYP 2C8 has part in the hydroxylation of the S-enantiomer (Ufer 2004, 2005).
No CYP relevant drug-drug interaction with phenprocoumon as a perpetrator has been reported in the literature (Drugbank, Lexi-Interact, Micromedex, SPC).
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
Ufer M, Svensson JO et al. Eur J Clin Pharmacol. 2004 May;60(3):173-82. |
15054565 |
| 2. | Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
Ufer M. Clin Pharmacokinet. 2005;44(12):1227-46. |
16372822 |
| * | Drug reference publications | |
| 3. | DrugBank. Phenprocoumon.
|
|
| * | Drug interaction databases | |
| 4. | Lexi-Interact, via UpToDate.
|
|
| 5. | Micromedex® 2.0 (online). Drug Interactions). (24.05.2017).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Luxembourg© NAPOS 2024